Onco Actu du 27 août 2015

	3.1 Tabac
The great e-cigarette war [BBC News] E-cigarettes are far less harmful than tobacco and could be prescribed to help smokers quit, a report in England found. But the Welsh government wants to ban their use in public places. Why are approaches in the neighbouring countries so different?
	4.1 Dép., diag. & prono. - Prostate
Cancer sniffing dogs to aid British doctors [Reuters] Dr. Guest says dogs can detect the scent of cancer almost instantly, meaning they could potentially check many more samples than a human could possibly do.
	4.12 Biopsies liquides
New ‘mutation-tracking’ blood test could predict breast cancer relapse months in advance [The Institute of Cancer Research] The study, published in the journal Science Translational Medicine, is an important step towards use of ‘liquid biopsies’ to revolutionise breast cancer care – by changing the way cancer is monitored in the clinic and informing treatment decisions.
Sequenom Enters Collaboration With UC San Diego Moores Cancer Center With Novel Liquid Biopsy Assay [Sequenom] Sequenom, through its wholly owned subsidiary Sequenom Laboratories, intends to carry out further studies in order to bring to market a liquid biopsy assay for use in patient care in 2016.
Simple blood test detects breast cancer relapse seven months early [The Guardian] The researchers say it is an important step towards use of ‘liquid biopsies’ to revolutionise breast cancer care in changing the way cancer is monitored and helping doctors decide on the best treatments.
	4.9 Dép., diag. & prono. - Sein
High Proportion of Women Experience Anxiety Following False-positive Screening Mammography [AACR] Bolejko and colleagues used the Swedish Consequences of Screening – Breast Cancer (COS-BC) questionnaire to investigate the extent of psychosocial consequences of false-positive screening mammography among 399 women who were enrolled in the study immediately after recall to the diagnostic work-up following an abnormal mammogram, and later being considered that breast cancer was not found.
Treating ‘stage 0’ breast cancer doesn’t always save women’s lives so should we screen for it? [The Conversation] Choice does not solve the fundamental dilemma of screening: is it ethically acceptable to cause serious harm in some people in order to improve the prognosis of others?
	5. Traitements
Our milestones: Cisplatin – the story of a platinum-selling life-saver [Cancer Research UK] In the latest in Our Milestones series, we go back to the 1970s to look at how Cancer Research UK scientists played a role in a global quest to develop and fine-tune one of the world’s most successful cancer drugs.
Laser detects brain tumour during surgery [The Telegraph] The procedure, carried out for the first time in Europe, meant doctors could work out how much tissue to remove, by measuring the light reflected from it.
	5.12 Immunothérapies
Immunotherapy agent benefits patients with drug-resistant multiple myeloma in first human trial [Dana-Farber Cancer Institute] In its first clinical trial, a breakthrough antibody therapy (daratumumab) produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments.
	5.2 Pharma
Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences [Cellectis] Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).
	5.2.1 Pharma - Partenariats
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer [Pfizer] This global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (NSABP) and PrECOG, LLC (PrECOG).
	5.2.3 Pharma - économie
Verastem shares crater on Twitter chatter around cancer data [FierceBiotech] Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response rate for KRAS mutant non-small cell lung cancer.
Biotech Selloff Has No Effect on Cellectis (CLLS) Advances: CEO [TheStreet] Choulika said the differences between Cellectis and its competitors are that his method ensures an adequate amount of T cells, and offers patients immediate treatments at a lower cost.
	6. Lutte contre les cancers
Is This the Future of Clinical Trials for Cancer? Stanley Hamilton on the NCI’s New MATCH Trial [Mendelspod] Stanley’s lab has chosen to use Thermo Fisher’s Ion sequencers to characterize the patients’ genomic pathways. Why? Find out the answer to these questions in today’s interview with one of the leading PI’s for this unique clinical trial.
	6.1 Observation
Chance of getting second cancer diagnosis on the rise [The Globe & Mail] About 19 per cent of cancers in the United States now are second-or-more cases, a recent study found. In the 1970s, it was only 9 per cent. Over that period, the number of first cancers rose 70 per cent while the number of second cancers rose 300 per cent.
	6.5 Médecines alternatives
Acupuncture bait and switch: Electrified hot flash edition [Respectful Insolence] When this study was presented as an abstract at the San Antonio Breast Cancer Symposium in December, similar stories were written about it. Of course, given the depth and breadth of science presented at the SABCS, it never ceases to amaze me how the press always seems to zero in on studies like this one, which tell us very little but give the appearance that acupuncture works.
	6.6 Publications
ASCO and UICC Collaborate to Extend Reach of Journal of Global Oncology [ASCO] The American Society of Clinical Oncology (ASCO) and the Union for International Cancer Control (UICC) announced today their partnership to expand the reach of the Journal of Global Oncology (JGO), a new open-access journal that will focus on cancer care, research, and care delivery issues unique to countries and settings with limited healthcare resources.
	6.7 DMP, Big Data & applis
Electronic trigger reduces delays in evaluation for cancer diagnosis [Baylor] “Our computerized triggers scanned huge amounts of patient data in the electronic health record and flagged individuals at risk for delays in follow-up of cancer-related abnormal clinical findings.”